Gilead Sciences Intrinsic Value Calculator – GILEAD SCIENCES Reports Total Revenue of USD 7.0 Billion for Third Quarter of FY 2023, Up 0.1% Y-o-Y

🌥️Earnings Overview

For the third quarter of Fiscal Year 2023, GILEAD SCIENCES ($NASDAQ:GILD) achieved total revenue of USD 7.0 billion, a slight 0.1% rise from the same quarter in the previous year. Net income for the quarter was USD 2.2 billion, an increase of 21.8% from the same quarter in the prior year.

Analysis – Gilead Sciences Intrinsic Value Calculator

GoodWhale has conducted an analysis of the fundamentals of GILEAD SCIENCES. After a thorough evaluation, GoodWhale’s proprietary Valuation Line has calculated the fair value of GILEAD SCIENCES share to be around $72.0. However, the current price of the stock is $80.6, meaning that it is currently overvalued by 11.9%. This could be an opportunity for investors looking for stocks that are currently trading at a fair price. More…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Gilead Sciences. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Gilead Sciences. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Gilead Sciences. More…

Key Ratios Snapshot

Some of the financial key ratios for Gilead Sciences are shown below. More…

Peers

In the biopharmaceutical industry, competition is fierce. Among the companies vying for market share are Gilead Sciences Inc, Eli Lilly and Co, Amgen Inc, and SCYNEXIS Inc. All of these companies are working to develop new and innovative treatments for a variety of diseases.

– Eli Lilly and Co ($NYSE:LLY)

Eli Lilly and Co is a pharmaceutical company with a market cap of 316.8 billion as of May 2021. The company has a return on equity of 45.88% and is headquartered in Indianapolis, Indiana. Eli Lilly and Co develops and markets prescription medications and over-the-counter products. The company’s products are available in approximately 120 countries.

– Amgen Inc ($NASDAQ:AMGN)

Amgen Inc is a biopharmaceutical company with a market cap of 135.3B as of 2022. The company has a return on equity of 460.37%. Amgen Inc is a biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics worldwide. The company offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and nephrology.

– SCYNEXIS Inc ($NASDAQ:SCYX)

SCYNEXIS Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. The company’s lead product, SCY-078, is an oral and intravenous antifungal agent in Phase 3 clinical development for the treatment of serious and life-threatening invasive fungal infections. SCYNEXIS Inc. was founded by Peter R. Lupton, David P. Lupton and George W. Schmidt in December 1997 and is headquartered in Durham, NC.

Summary

GILEAD SCIENCES reported strong financial results for the third quarter of Fiscal Year 2023, with total revenue of USD 7.0 billion and net income of USD 2.2 billion. This represented a slight increase in revenue from the same period last year, while net income was up 21.8%. This positive performance suggests that investors should consider Gilead Sciences as a good opportunity for long-term investing. The company has a diverse portfolio of products and services, a strong balance sheet, and a long track record of delivering strong financial returns.